WO2024064782A2 - Capsides de virus adéno-associé - Google Patents
Capsides de virus adéno-associé Download PDFInfo
- Publication number
- WO2024064782A2 WO2024064782A2 PCT/US2023/074729 US2023074729W WO2024064782A2 WO 2024064782 A2 WO2024064782 A2 WO 2024064782A2 US 2023074729 W US2023074729 W US 2023074729W WO 2024064782 A2 WO2024064782 A2 WO 2024064782A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acids
- acid sequence
- amino acid
- sequence identity
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 16
- 210000000234 capsid Anatomy 0.000 title claims description 134
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 411
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 410
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 51
- 150000001413 amino acids Chemical class 0.000 claims description 1473
- 108091033319 polynucleotide Proteins 0.000 claims description 308
- 102000040430 polynucleotide Human genes 0.000 claims description 308
- 239000002157 polynucleotide Substances 0.000 claims description 308
- 239000013598 vector Substances 0.000 claims description 94
- 210000004027 cell Anatomy 0.000 claims description 79
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 108700019146 Transgenes Proteins 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 238000004806 packaging method and process Methods 0.000 claims description 41
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 241000701022 Cytomegalovirus Species 0.000 claims description 15
- 150000007513 acids Chemical class 0.000 claims description 15
- -1 antagomir Proteins 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 9
- 108091070501 miRNA Proteins 0.000 claims description 8
- 239000002679 microRNA Substances 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- 241000282465 Canis Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 108020005004 Guide RNA Proteins 0.000 claims description 4
- 108091008103 RNA aptamers Proteins 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 239000002924 silencing RNA Substances 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 3
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 3
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 3
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 3
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 3
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 184
- 239000000203 mixture Substances 0.000 abstract description 100
- 102000039446 nucleic acids Human genes 0.000 abstract description 16
- 108020004707 nucleic acids Proteins 0.000 abstract description 16
- 230000014509 gene expression Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 21
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 14
- 101710163270 Nuclease Proteins 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 9
- 108091033409 CRISPR Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 6
- 241000700584 Simplexvirus Species 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 101710114762 50S ribosomal protein L11, chloroplastic Proteins 0.000 description 3
- 101710164994 50S ribosomal protein L13, chloroplastic Proteins 0.000 description 3
- 101710139119 50S ribosomal protein L27, chloroplastic Proteins 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 210000004507 artificial chromosome Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102100022146 Arylsulfatase A Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 2
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 2
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 2
- 102000017852 Saposin Human genes 0.000 description 2
- 108050007079 Saposin Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- WDVIDPRACNGFPP-QWRGUYRKSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WDVIDPRACNGFPP-QWRGUYRKSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Natural products O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100031794 Alcohol dehydrogenase 6 Human genes 0.000 description 1
- 101710187542 Alcohol dehydrogenase 6 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 101710190943 Angiogenin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 102100037320 Apolipoprotein A-IV Human genes 0.000 description 1
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 1
- 102100036451 Apolipoprotein C-I Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 101000692648 Avena sativa Phytochrome A type 3 Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100022440 Battenin Human genes 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100025580 Calmodulin-1 Human genes 0.000 description 1
- 101710164735 Calmodulin-1 Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100031089 Cystinosin Human genes 0.000 description 1
- 101710092486 Cystinosin Proteins 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100028875 Formylglycine-generating enzyme Human genes 0.000 description 1
- 101710192607 Formylglycine-generating enzyme Proteins 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100023364 Ganglioside GM2 activator Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 241001428016 Glaucosciadium clade Species 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108091060210 Heavy strand Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 102100034629 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000984164 Homo sapiens Calmodulin-1 Proteins 0.000 description 1
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 1
- 101001058231 Homo sapiens Gamma-enolase Proteins 0.000 description 1
- 101000685969 Homo sapiens Ganglioside GM2 activator Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 description 1
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 108010086123 Macrophage-Activating Factors Proteins 0.000 description 1
- 102000007436 Macrophage-Activating Factors Human genes 0.000 description 1
- 102100026158 Melanophilin Human genes 0.000 description 1
- 101710158003 Melanophilin Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 102100026502 Mucolipin-1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 1
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 description 1
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 description 1
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710192761 Serine-type anaerobic sulfatase-maturating enzyme Proteins 0.000 description 1
- 102100023105 Sialin Human genes 0.000 description 1
- 101710105284 Sialin Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- 101150068034 UL30 gene Proteins 0.000 description 1
- 101150099321 UL42 gene Proteins 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 229960003122 alglucerase Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 108010054327 angiotrofin Proteins 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229950002817 burosumab Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 108010023376 caplacizumab Proteins 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950004645 emapalumab Drugs 0.000 description 1
- 229950006925 emicizumab Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 229950006063 eptinezumab Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229950011509 fremanezumab Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229950000118 galcanezumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- 102000049157 human CALM1 Human genes 0.000 description 1
- 102000053929 human ENO2 Human genes 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 102000056556 human TTR Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229950005287 lanadelumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960002915 nebacumab Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 description 1
- 102000006581 rab27 GTP-Binding Proteins Human genes 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229950007085 ravulizumab Drugs 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 229950001460 sacituzumab Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Definitions
- Adeno-associated viruses are small, non-enveloped viruses of the genus Dependoviruses within the family Parvoviridae. They package a single-stranded DNA genome that is approximately 4.7kb in length, consisting of rep and cap genes flanked by inverted terminal repeat regions (ITRs). AAVs are an ideal delivery system for gene therapy because AAV infection of cells in culture is non-cytopathic, and natural infection of humans and other animals is silent.
- the signals directing AAV replication, genome encapsidation and integration are contained within the inverted terminal repeats (ITRs) of the AAV genome, essentially all of the internal 4.7 kb of the AAV genome (encoding the replication and structural capsid proteins, repcap) can be replaced with heterologous nucleic acid sequences, such as a transgene for effecting gene therapy.
- ITRs inverted terminal repeats
- Recombinant AAV (rAAV) gene therapy vectors typically consist of a recombinant AAV genome comprising a gene therapy transgene, packaged within an AAV capsid.
- the AAV capsid which is formed by an assembly of 60 AAV capsid proteins, interacts with the cell surface of target cells and determines the tropism and transduction efficiency of rAAV.
- tissue-specific genetic diseases it is desirable to have rAAVs that can specifically and efficiently target tissues in need of gene therapy.
- AAV adeno-associated virus
- the instant disclosure provides a recombinant adeno- associated virus (AAV) capsid protein comprising: (i) an amino acid sequence having at least 94% sequence identity to amino acids 1-734 of SEQ ID NO: 2, an amino acid sequence having at least 95% sequence identity to amino acids 137-734 of SEQ ID NO: 2, and/or an amino acid sequence having at least 96% sequence identity to amino acids 202-734 of SEQ ID NO: 2: (ii) an amino acid sequence having at least 96% sequence identity to amino acids 1-736 of SEQ ID NO: 4, an amino acid sequence having at least 95% sequence identity to amino acids 138-736 of SEQ ID NO: 4, and/or an amino acid sequence having at least 96% sequence identity to amino acids 204-736 of SEQ ID NO: 4; (iii) an amino acid sequence having at least 94% sequence identity to amino acids 1-734 of SEQ ID NO: 6.
- AAV adeno- associated virus
- amino acid sequence having at least 95% sequence identity to amino acids 1-735 of SEQ ID NO: 32 an amino acid sequence having at least 95% sequence identity to amino acids 137-735 of SEQ ID NO: 32, and/or an amino acid sequence having at least 96% sequence identity to amino acids 202-735 of SEQ ID NO: 32;
- the instant disclosure provides a recombinant AAV capsid protein comprising: (i) an amino acid sequence having at least 99% sequence identity to amino acids 1-734 of SEQ ID NO: 2. an amino acid sequence having at least 99% sequence identity to amino acids 137-734 of SEQ ID NO: 2, and/or an amino acid sequence having at least 99% sequence identity to amino acids 202-734 of SEQ ID NO: 2; (ii) an amino acid sequence having at least 99% sequence identity to amino acids 1-736 of SEQ ID NO: 4, an amino acid sequence having at least 99% sequence identity to amino acids 138-736 of SEQ ID NO: 4, and/or an amino acid sequence having at least 99% sequence identity to amino acids 204-736 of SEQ ID NO: 4; (iii) an amino acid sequence having at least 99% sequence identity to amino acids 1-734 of SEQ ID NO: 6, an amino acid sequence having at least 99% sequence identity to amino acids 137-734 of SEQ ID NO: 6, and/or an amino acid sequence having at
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 2, amino acids 137-734 of SEQ ID NO: 2, and/or amino acids 202- 734 of SEQ ID NO: 2. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 2.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 4. amino acids 138-736 of SEQ ID NO: 4, and/or amino acids 204-
- the recombinant AAV capsid protein comprises SEQ ID NO: 4.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 6. amino acids 137-734 of SEQ ID NO: 6, and/or amino acids 202- 734 of SEQ ID NO: 6. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 6.
- the recombinant AAV capsid protein comprises amino acids 1-731 of SEQ ID NO: 8. amino acids 134-731 of SEQ ID NO: 8, and/or amino acids 199- 731 of SEQ ID NO: 8. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 10.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 12, amino acids 137-736 of SEQ ID NO: 12, and/or amino acids 203- 736 of SEQ ID NO: 12. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 12.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 14, amino acids 138-736 of SEQ ID NO: 14, and/or amino acids 204- 736 of SEQ ID NO: 14. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 14.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 16, amino acids 137-734 of SEQ ID NO: 16, and/or amino acids 202- 734 of SEQ ID NO: 16. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 16.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 18, amino acids 138-735 of SEQ ID NO: 18, and/or amino acids 203-
- the recombinant AAV capsid protein comprises SEQ ID NO: 18.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 20, amino acids 137-736 of SEQ ID NO: 20, and/or amino acids 202-
- the recombinant AAV capsid protein comprises SEQ ID NO: 20.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 22, amino acids 137-736 of SEQ ID NO: 22, and/or amino acids 203- 736 of SEQ ID NO: 22. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 22.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 24, amino acids 138-736 of SEQ ID NO: 24, and/or amino acids 204- 736 of SEQ ID NO: 24. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 24.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 26, amino acids 137-735 of SEQ ID NO: 26, and/or amino acids 202- 735 of SEQ ID NO: 26. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 26.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 28, amino acids 137-734 of SEQ ID NO: 28, and/or amino acids 202- 734 of SEQ ID NO: 28. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 28.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 30, amino acids 137-734 of SEQ ID NO: 30, and/or amino acids 202-
- the recombinant AAV capsid protein comprises SEQ ID NO: 30.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 32, amino acids 137-735 of SEQ ID NO: 32, and/or amino acids 202-
- the recombinant AAV capsid protein comprises SEQ ID NO: 32.
- the recombinant AAV capsid protein comprises amino acids 1 -735 of SEQ ID NO: 34, amino acids 137-735 of SEQ ID NO: 34, and/or amino acids 202- 735 of SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 36, amino acids 138-735 of SEQ ID NO: 36, and/or amino acids 203- 735 of SEQ ID NO: 36. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 36.
- the recombinant AAV capsid protein comprises amino acids 1-731 of SEQ ID NO: 38, amino acids 134-731 of SEQ ID NO: 38, and/or amino acids 199- 731 of SEQ ID NO: 38. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 38.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 40, amino acids 137-735 of SEQ ID NO: 40, and/or amino acids 203-
- the recombinant AAV capsid protein comprises SEQ ID NO: 40.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 42, amino acids 138-736 of SEQ ID NO: 42, and/or amino acids 204-
- the recombinant AAV capsid protein comprises SEQ ID NO: 42.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 44, amino acids 137-736 of SEQ ID NO: 44, and/or amino acids 202- 736 of SEQ ID NO: 44. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 44.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 46, amino acids 137-736 of SEQ ID NO: 46, and/or amino acids 203- 736 of SEQ ID NO: 46. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 46.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 48, amino acids 137-734 of SEQ ID NO: 48, and/or amino acids 202- 734 of SEQ ID NO: 48. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 48.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 50, amino acids 137-734 of SEQ ID NO: 50, and/or amino acids 202- 734 of SEQ ID NO: 50. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 50.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 52, amino acids 137-734 of SEQ ID NO: 52, and/or amino acids 202-
- the recombinant AAV capsid protein comprises SEQ ID NO: 52.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 54, amino acids 138-735 of SEQ ID NO: 54, and/or amino acids 203-
- the recombinant AAV capsid protein comprises SEQ ID NO: 54.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 56, amino acids 137-735 of SEQ ID NO: 56, and/or amino acids 202- 735 of SEQ ID NO: 56. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 56.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 58, amino acids 137-735 of SEQ ID NO: 58, and/or amino acids 202- 735 of SEQ ID NO: 58. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 58.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 60, amino acids 137-735 of SEQ ID NO: 60, and/or amino acids 202- 735 of SEQ ID NO: 60. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 60.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 62, amino acids 137-735 of SEQ ID NO: 62, and/or amino acids 202- 735 of SEQ ID NO: 62. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 62.
- the recombinant AAV capsid protein of the present disclosure is a variant of a clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, clade I, AAVgo. 1, AAV3, AAV4, AAV10, AAV11, AAV12, rh.32, rh32.33, rh.33, rh.34, BAAV, or AAV5 capsid protein.
- the instant disclosure provides an isolated polynucleotide encoding a recombinant AAV capsid protein as described in the instant disclosure.
- the isolated polynucleotide has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the nucleic acid sequence set forth in any one of SEQ ID NOs: 1, 3. 5, 7, 9. 11.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11. 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61.
- the instant disclosure provides a vector comprising an isolated polynucleotide as described in the instant disclosure.
- the vector is a plasmid or a viral vector.
- the viral vector is a retrovirus vector, a herpes virus vector, a baculovirus vector, or an adenovirus vector.
- the vector is an expression vector.
- the instant disclosure provides a recombinant cell comprising a polynucleotide as described in the instant disclosure or a vector as described in the instant disclosure.
- the instant disclosure provides a method of producing a recombinant AAV capsid protein, the method comprising culturing a recombinant cell as described in the instant disclosure under conditions where the polynucleotide is expressed, and the capsid protein is produced.
- the instant disclosure provides a recombinant adeno-associated virus (rAAV) comprising: (a) a capsid comprising one or more of the recombinant AAV capsid proteins of the instant disclosure; and (b) an rAAV genome.
- the rAAV genome comprises a transgene.
- the transgene encodes a polypeptide.
- the transgene encodes a miRNA, shRNA, siRNA, antisense RNA, gRNA, antagomir, miRNA sponge, RNA aptazyme, RNA aptamer, IncRNA. ribozyme or mRNA.
- the transgene is operably linked to a transcriptional regulatory element.
- the instant disclosure provides a method for transducing a cell, the method comprising contacting the cell with a rAAV of the instant disclosure under conditions whereby the cell is transduced.
- the instant disclosure provides a method for delivering a transgene in a cell, the method comprising contacting the cell with a rAAV of the instant disclosure under conditions whereby the cell is transduced and the transgene is expressed.
- the cell is in a subject and the rAAV is administered to the subject.
- the cell is a muscle cell and/or a liver cell.
- the rAAV is administered to the subject intravenously, intraperitoneally, subcutaneously, intramuscularly, intrathecally, or intradermally.
- the subject is selected from the group consisting of a human subject, a canine subject, a feline subject, and an equine subject.
- the subject is a human subject.
- the instant disclosure provides a recombinant AAV comprising: (a) a capsid comprising one or more of the recombinant AAV capsid proteins of the instant disclosure; and (b) an rAAV genome, for use in medicine, for use as therapy, or for use as a medicament.
- the instant disclosure provides a packaging system for preparation of an rAAV, wherein the packaging system comprises: (a) a first nucleotide sequence encoding one or more AAV Rep proteins; (b) a second nucleotide sequence encoding a recombinant AAV capsid protein of the instant disclosure; and (c) a third nucleotide sequence comprising an rAAV genome sequence.
- the packaging system comprises a first vector compnsing the first nucleotide sequence and the second nucleotide sequence, and a second vector comprising the third nucleotide sequence.
- the packaging system of the instant disclosure further comprises a fourth nucleotide sequence comprising one or more helper virus genes.
- the fourth nucleotide sequence is comprised within a third vector.
- the fourth nucleotide sequence comprises one or more genes from a virus selected from the group consisting of adenovirus, herpesvirus, vaccinia virus, and cytomegalovirus (CMV).
- CMV cytomegalovirus
- the first vector, second vector, and/or the third vector of the packaging system of the instant disclosure is a plasmid.
- the instant disclosure provides a method for recombinant preparation of an rAAV, the method comprising introducing the packaging system as described in the instant disclosure into a cell under conditions whereby the rAAV is produced.
- FIG. 1 shows the expression level of FGF21 (FIG. 1A) or sTGFbR2 (FIG. IB) in plasma samples obtained from dogs intravenously administered 5 x 10 12 vg/kg of vector genomes comprising FGF21 and sTGFbR2 coding sequences packaged in CL01, CL03, CL11, CL13, CL27, or AAV8 (control) capsids.
- FIG. 1A shows the expression of FGF21 as assessed by ELISA
- FIG. IB shows the expression of sTGFbR2 as assessed by Western blot.
- AAV capsid proteins recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.
- AAV capsid proteins described herein have been isolated from screening a shuffled capsid library in vivo for AAVs that are enriched in the liver and/or muscle.
- AAV is a standard abbreviation for adeno-associated virus.
- rAAV recombinant adeno-associated virus
- capsid gene refers to a nucleic acid sequence that encodes a capsid protein.
- the capsid protein may be VP1, VP2, or VP3.
- VP1, VP2, and/or VP3 capsid proteins assemble into a capsid that surrounds the rAAV genome.
- the term “rep gene” refers to the nucleic acid sequences that encode the non-structural proteins (e.g., rep78, rep68, rep52, and rep40) required for the replication and production of an AAV.
- rAAV genome refers to a nucleic acid molecule (e.g., DNA and/or RNA) comprising the genome sequence of an rAAV.
- a nucleic acid molecule e.g., DNA and/or RNA
- the rAAV genome can be in the sense or antisense orientation relative to the direction of transcription of the transgene.
- an “isolated polynucleotide” refers to a polynucleotide that has been separated from one or more nucleic acid molecules present in the natural source of the polynucleotide.
- the “percentage identity” between two nucleotide sequences or between two amino acid sequences is calculated by multiplying the number of matches between the pair of aligned sequences by 100, and dividing by the length of the aligned region, including internal gaps. Identity scoring only counts perfect matches, and does not consider the degree of similarity of amino acids to one another. Note that only internal gaps are included in the length, not gaps at the sequence ends.
- a “vector” refers to a nucleic acid molecule that is a vehicle for introducing anucleic acid molecule (e.g., a polynucleotide disclosed herein) into a cell.
- an “expression vector” refers to a vector comprising transcriptional regulatory elements operably linked to a gene of interest (e.g., a polynucleotide disclosed herein) that facilitate the expression of the gene of interest in a cell and/or a cell free expression system.
- a gene of interest e.g., a polynucleotide disclosed herein
- transgene refers to a non-AAV nucleic acid sequence that encodes a polypeptide ( ⁇ ?.g., an antibody or scFv) or non-coding RNA ( ⁇ ?.g., an miRNA, shRNA, siRNA, antisense RNA, gRNA, antagomir, miRNA sponge, RNA aptazyme, or RNA aptamer).
- a polypeptide ⁇ ?.g., an antibody or scFv
- non-coding RNA ⁇ ?.g., an miRNA, shRNA, siRNA, antisense RNA, gRNA, antagomir, miRNA sponge, RNA aptazyme, or RNA aptamer.
- transcriptional regulatory element refers to a cis-acting nucleotide sequence, for example, a DNA sequence, that regulates (e.g., controls, increases, or reduces) transcription of an operably linked nucleotide sequence by an RNA polymerase to form an RNA molecule.
- a TRE may comprise one or more promoter elements and/or enhancer elements.
- promoter and enhancer elements in a gene may be close in location, and the term “promoter” may refer to a sequence comprising a promoter element and an enhancer element. Thus, the term “promoter” does not exclude an enhancer element in the sequence.
- the promoter and enhancer elements do not need to be derived from the same gene or species, and the sequence of each promoter or enhancer element may be either identical or substantially identical to the corresponding endogenous sequence in the genome.
- operably linked is used to describe the connection between a TRE and a polynucleotide sequence (e.g., a transgene disclosed herein) to be transcribed.
- gene expression is placed under the control of a TRE comprising one or more promoter and/or enhancer elements.
- the transgene is “operably linked” to the TRE if the transcription of the transgene is controlled or influenced by the TRE.
- the promoter and enhancer elements of the TRE may be in any orientation and/or distance from the trans gene, as long as the desired transcriptional activity is obtained.
- the TRE is upstream from the transgene.
- the term “effective amount” in the context of the administration of an AAV to a subject refers to the amount of the AAV that achieves a desired prophylactic or therapeutic effect.
- the present disclosure provides a recombinant adeno-associated virus (AAV) capsid protein.
- AAV capsid proteins described herein have been isolated from screening a shuffled capsid library in vivo for AAVs that are enriched in the liver and/or muscle.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 2.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%. at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 2.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 2. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 2. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 2. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 2.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 4.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 4.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 4.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 4. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-736 of SEQ ID NO: 4. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 204-736 of SEQ ID NO: 4. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 4.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 6.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 6.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 6.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 6. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 6. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 6. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 6.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%. at least 99%, or 100% identity to amino acids 1-731 of SEQ ID NO: 8.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity’ to amino acids 134-731 of SEQ ID NO: 8.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 8.
- the recombinant AAV capsid protein comprises amino acids 1-731 of SEQ ID NO: 8. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 134-731 of SEQ ID NO: 8. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 199-731 of SEQ ID NO: 8. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 8.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 10.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 10.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 10.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 10. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-736 of SEQ ID NO: 10. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-736 of SEQ ID NO: 10. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 10.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 12.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 12.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 12.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 12. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-736 of SEQ ID NO: 12. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-736 of SEQ ID NO: 12. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 12.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 1-736 of SEQ ID NO: 14.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 138-736 of SEQ ID NO: 14.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%. at least 87%. at least 88%.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 14. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-736 of SEQ ID NO: 14. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 204-736 of SEQ ID NO: 14. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 14.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 16.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 137-734 of SEQ ID NO: 16.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 16. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 16. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 16. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 16.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 18.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 18.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 18. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-735 of SEQ ID NO: 18. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-735 of SEQ ID NO: 18. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 18.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 20.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-736 of SEQ ID NO: 20.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 20. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-736 of SEQ ID NO: 20. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-736 of SEQ ID NO: 20. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 20.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 22.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 22.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 22.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 22. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-736 of SEQ ID NO: 22. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-736 of SEQ ID NO: 22. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 22.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 24.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 24.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 24. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-736 of SEQ ID NO: 24. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 204-736 of SEQ ID NO: 24. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 24.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 26.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 26.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 26.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 26. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 26. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 26. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 26.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 28.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 28.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 28. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 28. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 28. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 28.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 30.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 30.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 30.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 30. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 30. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 30. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 30.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 32.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 32.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 32. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 32. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 32. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 32.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 34. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 34. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 34. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 34.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 36.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 36.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 36. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-735 of SEQ ID NO: 36. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-735 of SEQ ID NO: 36. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 36.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-731 of SEQ ID NO: 38.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 134-731 of SEQ ID NO: 38.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 38.
- the recombinant AAV capsid protein comprises amino acids 1-731 of SEQ ID NO: 38. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 134-731 of SEQ ID NO: 38. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 199-731 of SEQ ID NO: 38. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 38.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 40.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 40.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 40. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 40. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-735 of SEQ ID NO: 40. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 40.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 42.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 42.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 42.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 42. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-736 of SEQ ID NO: 42. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 204-736 of SEQ ID NO: 42. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 42.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 44.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-736 of SEQ ID NO: 44.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 44. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-736 of SEQ ID NO: 44. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-736 of SEQ ID NO: 44. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 44.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 46.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 46.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 46.
- the recombinant AAV capsid protein comprises amino acids 1-736 of SEQ ID NO: 46. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-736 of SEQ ID NO: 46. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-736 of SEQ ID NO: 46. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 46.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 48.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 48.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 48. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 48. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 48. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 48.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 50.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 50.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 50.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 50. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 50. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 50. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 50.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 52.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 52.
- the recombinant AAV capsid protein comprises amino acids 1-734 of SEQ ID NO: 52. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-734 of SEQ ID NO: 52. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-734 of SEQ ID NO: 52. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 52.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 54.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 54.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 54.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 54. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 138-735 of SEQ ID NO: 54. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 203-735 of SEQ ID NO: 54. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 54.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 56.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 56.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 56. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 56. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 56. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 56.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 58.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 58.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 58.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 58. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 58. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 58. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 58.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 60.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 60.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 60. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 60. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 60. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 60.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 62.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 62.
- the recombinant AAV capsid protein comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 62.
- the recombinant AAV capsid protein comprises amino acids 1-735 of SEQ ID NO: 62. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 137-735 of SEQ ID NO: 62. In certain embodiments, the recombinant AAV capsid protein comprises amino acids 202-735 of SEQ ID NO: 62. In certain embodiments, the recombinant AAV capsid protein comprises SEQ ID NO: 62.
- the recombinant AAV capsid protein is a variant of a clade A, clade B, clade C, clade D, clade E, clade F, clade G. clade H, clade I, AAVgo. 1, AAV3, AAV4, AAV10, AAV11, AAV12. rh.32, rh32.33. rh.33, rh.34, BAAV. or AAV5 capsid protein.
- the present disclosure provides an isolated polynucleotide encoding one or more recombinant AAV capsid proteins as disclosed herein.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 2.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 2.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 2. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 2. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 2. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 2.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 4.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 4.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 4. In certain embodiments, the isolated polynucleotide encodes amino acids 138- 736 of SEQ ID NO: 4. In certain embodiments, the isolated polynucleotide encodes amino acids 204-736 of SEQ ID NO: 4. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 4.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 6.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 6.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%. at least 86%, at least 87%, at least 88%. at least 89%.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 6. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 6. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 6. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 6.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to amino acids 1-731 of SEQ ID NO: 8.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%. at least 89%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%. at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 8.
- the isolated polynucleotide encodes amino acids 1-731 of SEQ ID NO: 8. In certain embodiments, the isolated polynucleotide encodes amino acids 134- 731 of SEQ ID NO: 8. In certain embodiments, the isolated polynucleotide encodes amino acids 199-731 of SEQ ID NO: 8. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 8.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 10.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%. at least 87%, at least 88%, at least 89%, at least 90%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%. at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 10.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 10. In certain embodiments, the isolated polynucleotide encodes amino acids 138- 736 of SEQ ID NO: 10. In certain embodiments, the isolated polynucleotide encodes amino acids 203-736 of SEQ ID NO: 10. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 10.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1 -736 of SEQ ID NO: 12.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 12.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 12. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 736 of SEQ ID NO: 12. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 12.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 14.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 14.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 14. In certain embodiments, the isolated polynucleotide encodes amino acids 138- 736 of SEQ ID NO: 14. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 14.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 16.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 16.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 16.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 16. In certain embodiments, the isolated polynucleotide encodes amino acids 137-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 16.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 18.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 18.
- the isolated polynucleotide encodes an ammo acid sequence having at least 85%.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 18. In certain embodiments, the isolated polynucleotide encodes amino acids 138-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 18.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 20.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 20.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 20. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 736 of SEQ ID NO: 20. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 20.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 22.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 22.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%. at least 86%, at least 87%, at least 88%.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 22. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 736 of SEQ ID NO: 22. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 22.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 1-736 of SEQ ID NO: 24.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%. at least 87%, at least 88%, at least 89%, at least 90%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%. at least 89%. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 24.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 24. In certain embodiments, the isolated polynucleotide encodes amino acids 138- 736 of SEQ ID NO: 24. In certain embodiments, the isolated polynucleotide encodes amino acids 204-736 of SEQ ID NO: 24. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 24.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 1-735 of SEQ ID NO: 26.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%. at least 87%, at least 88%, at least 89%, at least 90%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%. at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 26.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 26. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 26. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 26. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 26.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 28.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 28.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 28. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 28. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 28. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 28.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 30.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 30.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 30. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 30. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 30. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 30.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 32.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 32.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 32.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 32. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 32. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 32. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 32.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 34.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 34.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 34. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 34. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 34. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 34.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 36.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 36.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 36.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 36. In certain embodiments, the isolated polynucleotide encodes amino acids 138- 735 of SEQ ID NO: 36. In certain embodiments, the isolated polynucleotide encodes amino acids 203-735 of SEQ ID NO: 36. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 36.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-731 of SEQ ID NO: 38.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 38.
- the isolated polynucleotide encodes amino acids 1-731 of SEQ ID NO: 38. In certain embodiments, the isolated polynucleotide encodes amino acids 134- 731 of SEQ ID NO: 38. In certain embodiments, the isolated polynucleotide encodes amino acids 199-731 of SEQ ID NO: 38. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 38.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 40.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 40.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 40.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 40. In certain embodiments, the isolated polynucleotide encodes amino acids 137-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 40.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 42.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 42.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 42. In certain embodiments, the isolated polynucleotide encodes amino acids 138-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 42.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 44.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 44.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-736 of SEQ ID NO: 44.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 44. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 736 of SEQ ID NO: 44. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 44.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 46.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 46.
- the isolated polynucleotide encodes amino acids 1-736 of SEQ ID NO: 46. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 736 of SEQ ID NO: 46. In certain embodiments, the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 46.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 48.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 48.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 48.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 48. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 48. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 48. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 48.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 50.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 50.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 50. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 734 of SEQ ID NO: 50. In certain embodiments, the isolated polynucleotide encodes amino acids 202-734 of SEQ ID NO: 50. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 50.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 52.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 52.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 52.
- the isolated polynucleotide encodes amino acids 1-734 of SEQ ID NO: 52. In certain embodiments, the isolated polynucleotide encodes amino acids 137-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 52.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 54.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 54.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 54. In certain embodiments, the isolated polynucleotide encodes amino acids 138-
- the isolated polynucleotide encodes amino acids
- the isolated polynucleotide encodes SEQ ID NO: 54.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 56.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 56.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 56.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 56. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 56. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 56. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 56.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 58.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 58.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 58. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 58. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 58. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 58.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 60.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 60.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 60.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 60. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 60. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 60. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 60.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 62.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the isolated polynucleotide encodes an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 62.
- the isolated polynucleotide encodes amino acids 1-735 of SEQ ID NO: 62. In certain embodiments, the isolated polynucleotide encodes amino acids 137- 735 of SEQ ID NO: 62. In certain embodiments, the isolated polynucleotide encodes amino acids 202-735 of SEQ ID NO: 62. In certain embodiments, the isolated polynucleotide encodes SEQ ID NO: 62.
- the present disclosure provides an isolated polynucleotide having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% sequence identity with the nucleic acid sequence set forth in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 3. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 5. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 7. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 9. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 11.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 13. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 15. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 17. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 19. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 23.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 25. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 27. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 29. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 31. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 33. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 35.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 37. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 39. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 41. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 43. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 45. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 47.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 49. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 51. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 53. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 55. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 57. In certain embodiments, the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 59.
- the isolated polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 61. [00195] In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 1 . In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 3. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 5. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 7.
- the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 9. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 13. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 15. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 17. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 19.
- the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 23. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 25. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 27. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 29.
- the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 31. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 33. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 35. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 37. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 39.
- the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 41. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 43. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 45. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 47. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 49.
- the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 51. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 53. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 55. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 57. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 59. In certain embodiments, the isolated polynucleotide consists of the nucleic acid sequence set forth in SEQ ID NO: 61.
- the polynucleotide is optimized, e.g, by codon/RNA optimization, replacement with heterologous signal sequences, and/or elimination of mRNA instability elements.
- Methods to generate optimized polynucleotides for recombinant expression by introducing codon changes and/or eliminating inhibitory regions in the mRNA can be carried out by adapting the optimization methods described in, e.g.. U.S. Patent Nos. 5,965.726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498, accordingly, all of which are herein incorporated by reference in their entireties.
- potential splice sites and instability elements within the RNA can be mutated without altering the amino acids encoded by the nucleic acid sequences to increase stability of the RNA for recombinant expression.
- the alterations utilize the degeneracy of the genetic code, e.g, using an alternative codon for an identical amino acid.
- Such methods can increase expression of the encoded capsid protein relative to the expression of the capsid encoded by polynucleotides that have not been optimized.
- the present disclosure provides a vector comprising a polynucleotide disclosed herein.
- Suitable vectors include, without limitation, plasmids, viruses, cosmids, artificial chromosomes, linear DNA, and mRNA.
- the vector is a plasmid or a viral vector.
- the vector is a retrovirus vector, a herpes virus vector, a baculovirus vector, or an adenovirus vector.
- the vector is an expression vector.
- Vectors e.g. , expression vectors
- the instant disclosure provides a recombinant cell comprising a polynucleotide or a vector (e.g., an expression vector) disclosed herein.
- the instant disclosure provides a method of producing an AAV capsid protein, the method comprising culturing the recombinant cell under conditions whereby the polynucleotide is expressed and the capsid is produced.
- Suitable vectors include, without limitation, plasmids, minimal vectors (e.g.. minicircles, NanoplasmidsTM, doggybones, MIDGE vectors, and the like), viruses, cosmids, artificial chromosomes, linear DNA, and mRNA.
- the first nucleic acid vector and/or the second nucleic acid vector is a DNA plasmid or a DNA minimal vector. Any DNA plasmid or DNA minimal vector that can accommodate the necessary vector elements can be used for the first nucleic acid vector and the second nucleic acid vector.
- Suitable DNA minimal vectors include, without limitation, linear covalently closed DNA (e.g., ministring DNA), linear covalently closed dumbbell shaped DNA (e.g, doggybone DNA, dumbbell DNA), minicircles, NanoplasmidsTM, minimalistic immunologically defined gene expression (MIDGE) vectors, and others known to those of skill in the art.
- DNA minimal vectors and their methods of production are described in, e.g., U.S. Patent Application Nos. 20100233814, 20120282283, 20130216562, 20150218565, 20150218586. 20160008488, 20160215296, 20160355827, 20190185924, 20200277624, and 20210010021, all of which are herein incorporated by reference in their entireties.
- a variety of host cells and expression vector systems can be utilized to express the capsid proteins described herein.
- Such expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells which can, when transformed or transfected with the appropriate nucleotide coding sequences, express a capsid protein described herein in situ.
- These include but are not limited to microorganisms such as bacteria (e.g., E. coli and B.
- subtilis transformed with, e.g., recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing capsid protein coding sequences; yeast (e.g, Saccharomyces Pichia) transformed with, e.g., recombinant yeast expression vectors containing capsid protein coding sequences; insect cell systems infected with, e.g., recombinant virus expression vectors (e.g., baculovirus) containing capsid protein coding sequences; plant cell systems (e.g...
- green algae such as Chlamydomonas reinhardtii
- recombinant virus expression vectors e.g, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV
- recombinant plasmid expression vectors e.g., recombinant plasmid expression vectors
- COS e.g., COS1 or COS
- CHO BHK, MDCK, HEK 293, NS0, PER.C6, VERO, CRL7O3O, HsS78Bst, HeLa, and NIH 3T3, HEK-293T, HepG2, SP210, Rl. l, B-W, L-M, BSC1, BSC40, YB/20 and BMT10 cells
- COS e.g., COS1 or COS
- CHO BHK, MDCK, HEK 293, NS0, PER.C6, VERO, CRL7O3O, HsS78Bst, HeLa, and NIH 3T3, HEK-293T, HepG2, SP210, Rl. l, B-W, L-M, BSC1, BSC40, YB/20 and BMT10 cells
- Rl. l B-W, L-M, BSC1, BSC40, YB/20 and BMT10
- recombinant expression constructs containing promoters derived from the genome of mammalian cells e.g., metallothionein promoter
- mammalian viruses e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter
- cells for expressing the capsid proteins described herein are human cells, e.g., human cell lines.
- a mammalian expression vector is pOptiVECTM or pcDNA3.3.
- bacterial cells such as Escherichia coli, or eukaryotic cells (e.g., mammalian cells) are used for the expression of a capsid protein.
- mammalian cells such as CHO or HEK293 cells, in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for capsid proteins disclosed herein.
- a number of expression vectors can be advantageously selected depending upon the use intended for the capsid protein being expressed. For example, when a large quantity of a capsid protein is to be produced, vectors which direct the expression of high levels of fusion protein products that are readily purified can be desirable. Such vectors include, but are not limited to, the E.
- coll expression vector pUR278 (Ruether U & Mueller-Hill B (1983) EMBO J 2: 1791-1794), in which the capsid protein coding sequence can be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; plN vectors (Inouye S & Inouye M (1985) Nuc Acids Res 13: 3101-3109; Van Heeke G & Schuster SM (1989) J Biol Chem 24: 5503-5509); and the like, all of which are herein incorporated by reference in their entireties.
- pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST).
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione.
- the pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
- Autographa californica nuclear polyhedrosis virus (AcNPV), for example, can be used as a vector to express foreign genes.
- the virus grows in Spodoptera frugiperda cells.
- the capsid protein coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
- a number of viral-based expression systems can be utilized.
- the capsid protein coding sequence of interest can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by in vitro or in vivo recombination.
- Insertion in a non-essential region of the viral genome will result in a recombinant virus that is viable and capable of expressing the capsid protein molecule in infected hosts (see, e.g., Logan J & Shenk T (1984) PNAS 81(12): 3655-9, which is herein incorporated by reference in its entirety ).
- Specific initiation signals can also be required for efficient translation of inserted capsid protein coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
- exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic.
- the efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g. , Bitter G et al. (1987) Methods Enzymol. 153: 516-544, which is herein incorporated by reference in its entirety).
- a host cell strain can be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g. cleavage) of protein products can be important for the function of the protein.
- Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
- eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used.
- Such mammalian host cells include but are not limited to CHO, VERO, BHK, Hela, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NSO (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, COS (e.g, COS1 or COS), PER.C6, VERO, HsS78Bst, HEK-293T, HepG2, SP210, Rl. l, B-W, L-M, BSC1, BSC40, YB/20, BMT10 and HsS78Bst cells.
- stable expression cells can be generated.
- cell lines which stably express a capsid protein described herein can be engineered.
- host cells can be transformed with a polynucleotide (e.g., DNA or RNA) controlled by appropriate transcriptional regulatory elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
- a polynucleotide e.g., DNA or RNA
- appropriate transcriptional regulatory elements e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.
- engineered cells can be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
- the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
- This method can advantageously be used to engineer cell lines which express a capsid protein described herein or a fragment thereof.
- a number of selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler M et al. (1977) Cell 11(1): 223-32); hypoxanthineguanine phosphoribosyltransferase (Szybalska EH & Szybalski W (1962) PNAS 48(12): 2026-2034); and adenine phosphoribosyltransferase (Lowy I et al. (1980) Cell 22(3): 817-23) genes in tk-, hgprt- or aprt-cells, respectively, all of which are herein incorporated by reference in their entireties.
- antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler M et al. (1980) PNAS 77(6): 3567-70; O’Hare K et al.
- the present disclosure provides an rAAV composition comprising a capsid comprising a recombinant AAV capsid protein disclosed herein.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 2.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 2.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 2.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 4.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 4.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity' to amino acids 204-736 of SEQ ID NO: 4.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 6.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 6.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 6.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to amino acids 1-731 of SEQ ID NO: 8.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 134-731 of SEQ ID NO: 8.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 8.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 10.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-736 of SEQ ID NO: 10.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 10.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 12.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 12.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 12.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 14.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 138-736 of SEQ ID NO: 14.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 14.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%. at least 90%, at least 91%, at least 92%. at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 1 .
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 16.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 16.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 18.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 18.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 18.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 20.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 20.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 202-736 of SEQ ID NO: 20.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 22.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 22.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 203-736 of SEQ ID NO: 22.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 24.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 138-736 of SEQ ID NO: 24.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 24.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 26.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 26.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%. at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 26.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 28.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 28.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 28.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 30.
- the rAAV composition comprises a capsid compnsing an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 30.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 30.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 32.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 32.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 32.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 34.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 34.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 34.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 36.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 36.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 36.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-731 of SEQ ID NO: 38.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 134-731 of SEQ ID NO: 38.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 199-731 of SEQ ID NO: 38.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 40.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 40.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-735 of SEQ ID NO: 40.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 42.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 204-736 of SEQ ID NO: 42.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 44.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity- to amino acids 137-736 of SEQ ID NO: 44.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-736 of SEQ ID NO: 44.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-736 of SEQ ID NO: 46.
- the rAAV composition comprises a capsid compnsing an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-736 of SEQ ID NO: 46.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 203-736 of SEQ ID NO: 46.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 48.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity- to amino acids 137-734 of SEQ ID NO: 48.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 48.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 50.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%. at least 92%. at least 93%.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 50.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-734 of SEQ ID NO: 52.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-734 of SEQ ID NO: 52.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-734 of SEQ ID NO: 52.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 54.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 138-735 of SEQ ID NO: 54.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity 7 to amino acids 203-735 of SEQ ID NO: 54.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 56.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 56.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 56.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 58.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 58.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 60.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 60.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 202-735 of SEQ ID NO: 60.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 1-735 of SEQ ID NO: 62.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to amino acids 137-735 of SEQ ID NO: 62.
- the rAAV composition comprises a capsid comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity' to amino acids 202-735 of SEQ ID NO: 62.
- the present disclosure provides an rAAV comprising a capsid compnsing one or more recombinant capsid proteins disclosed herein; and an rAAV genome.
- the rAAVs disclosed herein generally comprise a recombinant genome (e.g., an rAAV genome) packaged within the capsid.
- the rAAV genome can be of any ty pe that is capable of being packages within an AAV capsid disclosed herein.
- the rAAV genome is a single-stranded DNA genome.
- the rAAV genome is a self- complementary 7 genome, for example as described in US7790154, which is hereby incorporated by reference in its entirety.
- the rAAV genome comprises a trans gene.
- the transgene encodes a polypeptide.
- the transgene encodes a therapeutic protein.
- the transgene encodes an antibody or a fragment thereof (e g. , a Fab, scFv, or full-length antibody).
- the transgene encodes an scFv, nanobody, or VHH.
- the transgene encodes a non-coding RNA.
- the transgene comprises one or more sequences encoding an RNA molecule.
- RNA molecules include, without limitation, miRNA, shRNA, siRNA, antisense RNA, gRNA, antagomirs, miRNA sponges, RNA aptazymes, RNA aptamers, mRNA, IncRNAs, ribozymes, and synthetic RNAs known in the art.
- the transgene encodes one or more polypeptides, or a fragment thereof.
- Such transgenes can comprise the complete coding sequence of a polypeptide, or only a fragment of a coding sequence of a polypeptide.
- the transgene encodes a polypeptide that is useful to treat a disease or disorder in a subject.
- Suitable polypeptides include, without limitation, (3-globin, hemoglobin, tissue plasminogen activator, and coagulation factors; colony stimulating factors (CSF); interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, etc.; growth factors, such as keratinocyte growth factor (KGF).
- CSF colony stimulating factors
- interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, etc.
- growth factors such as keratinocyte growth factor (KGF).
- SCF stem cell factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- IGFs insulin-like growth factors
- BMP bone morphogenetic protein
- EGF epidermal growth factor
- GDF-9 growth differentiation factor-9
- HDGF hepatoma derived growth factor
- GDF-8 nerve growth factor
- soluble receptors such as soluble TNF-a receptors, soluble interleukin receptors (e.g., soluble IL-1 receptors and soluble type II IL-1 receptors), soluble y/A T cell receptors, ligand-binding fragments of a soluble receptor, and the like; enzymes, such as a-glucosidase, imiglucerase, P- glucocerebrosidase, and alglucerase; enzyme activators, such as tissue plasminogen activator; chemokines, such as IP-10, monokine induced by interferon-gamma (Mig), Groa/IL-8, RANTES, MIP-la, MIP-ip, MCP-1, PF-4, and the
- VEGF121, VEGF165, VEGF-C, VEGF-2 glioma-derived growth factor, angiogenin, angiogenin-2; and the like; anti- angiogenic agents, such as a soluble VEGF receptor; protein vaccine; neuroactive peptides, such as nerve grow th factor (NGF), bradykinin, cholecystokinin, gastrin, secretin, oxytocin, gonadotropin-releasing hormone, beta-endorphin, enkephalin, substance P, somatostatin, prolactin, galanin, growth hormone-releasing hormone, bombesin, dynorphin, warfarin, neurotensin, motilin, thyrotropin, neuropeptide Y, luteinizing hormone, calcitonin, insulin, glucagons, vasopressin, angiotensin II, thyrotropin-releasing hormone, vasoactive intestinal peptide, a sleep
- the transgene encodes a protein that may be defective in one or more lysosomal storage diseases.
- suitable proteins include, without limitation, a-sialidase, cathepsin A, a-mannosidase, P-mannosidase, glycosyl asparaginase, a-fucosidase, a-N- acetylglucosaminidase, P-galactosidase, P-hexosaminidase a-subunit, P-hexosaminidase P- subunit, GM2 activator protein, glucocerebrosidase, Saposin C, Arylsulfatase A, Saposin B, formyl-glycine generating enzyme, P-galactosylceramidase, a-galactosidase A, iduronate sulfatase, a-iduronidase, hepara
- the transgene encodes an antibody or a fragment thereof (e.g., a Fab, scFv. or full-length antibody).
- Suitable antibodies include, without limitation, muromonab-cd3, efalizumab, tositumomab, daclizumab, nebacumab, catumaxomab, edrecolomab, abciximab, rituximab, basiliximab, palivizumab, infliximab, trastuzumab, adalimumab, ibritumomab tiuxetan, omalizumab, cetuximab, bevacizumab, natalizumab, panitumumab, ranibizumab, eculizumab, certolizumab, ustekinumab, canakinumab, golimumab, ofatum
- tocilizumab denosumab. belimumab, ipilimumab. brentuximab vedotin, pertuzumab, raxibacumab, obinutuzumab, alemtuzumab, siltuximab, ramucirumab, vedolizumab, blinatumomab, nivolumab, pembrolizumab, idarucizumab, necitumumab, dinutuximab, secukinumab, mepolizumab, alirocumab, evolocumab, daratumumab, elotuzumab, ixekizumab, reslizumab.
- olaratumab bezlotoxumab, atezolizumab, obiltoxaximab, inotuzumab ozogamicin, brodalumab, guselkumab, dupilumab, sarilumab, avelumab, ocrehzumab, emicizumab, benralizumab, gemtuzumab ozogamicin, durvalumab.
- burosumab erenumab, galcanezumab, lanadelumab, mogamulizumab, tildrakizumab, cemiplimab, fremanezumab, ravulizumab, emapalumab, ibalizumab, moxetumomab, caplacizumab, romosozumab, risankizumab, polatuzumab. eptinezumab, leronlimab, sacituzumab. brolucizumab, isatuximab. and teprotumumab.
- the transgene encodes a nuclease.
- Suitable nucleases include, without limitation, zinc fingers nucleases (ZFN) (see, e.g., Porteus, and Baltimore (2003) Science 300: 763; Miller et al. (2007) Nat. Biotechnol. 25:778-785; Sander et al. (2011) Nature Methods 8:67-69; and Wood et al. (2011) Science 333:307, each of which is hereby incorporated by reference in its entirety); transcription activator-like effectors nucleases (TALEN) (see, e.g., Wood et al. (2011) Science 333:307; Boch et al.
- ZFN zinc fingers nucleases
- TALEN transcription activator-like effectors nucleases
- the transgene encodes an RNA-guided nuclease.
- Suitable RNA-guided nucleases include, without limitation, Class I and Class II clustered regularly interspaced short palindromic repeats (CRISPR)-associated nucleases.
- Class I is divided into types I, III, and IV, and includes, without limitation, type I (Cas3), type I-A (Cas8a, Cas5), type I-B (Cas8b), type I-C (Cas8c), type 1-D (CaslOd), type I-E (Csel, Cse2), type I-F (Csyl, Csy2, Csy3), type I-U (GSU0054), type III (CaslO), type III-A (Csm2), type III-B (Cmr5), type III-C (CsxlO or Csxl 1), type III-D (CsxlO), and type IV (Csfl).
- type I Cas3
- type I-A Cas8a, Cas5
- type I-B Cas8b
- type I-C Cas8c
- type 1-D CaslOd
- type I-E Csel, Cs
- Class II is divided into types II, V, and VI, and includes, without limitation, type II (Cas9), type 1I-A (Csn2), type Il-B (Cas4), type V (Cpfl, C2cl, C2c3), and type VI (Casl3a, Casl3b, Casl3c).
- RNA-guided nucleases also include naturally-occurring Class II CRISPR nucleases such as Cas9 (Type II) or Casl2a/Cpfl (Type V), as well as other nucleases derived or obtained therefrom.
- Exemplary Cas9 nucleases that may be used in the present invention include, but are not limited to, S', pyogenes Cas9 (SpCas9), S’, aureus Cas9 (SaCas9), N. meningitidis Cas9 (NmCas9), C. jejuni Cas9 (CjCas9), and Geobacillus Cas9 (GeoCas9).
- the transgene encodes reporter sequences, which upon expression produce a detectable signal.
- reporter sequences include, without limitation, DNA sequences encoding P-lactamase, P -galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), red fluorescent protein (RFP), chloramphenicol acetyltransferase (CAT), luciferase, membrane bound proteins including, for example, CD2, CD4, CD8, the influenza hemagglutinin protein, and others well known in the art, to which high affinity antibodies directed thereto exist or can be produced by conventional means, and fusion proteins comprising a membrane bound protein appropriately fused to an antigen tag domain from, among others, hemagglutinin or Myc.
- the rAAV genome comprises a transcriptional regulatory' element (TRE) operably linked to the transgene, to control expression of an RNA or polypeptide encoded by the transgene.
- the TRE comprises a constitutive promoter.
- the TRE can be active in any mammalian cell e.g., any human cell).
- the TRE is active in a broad range of human cells.
- Such TREs may comprise constitutive promoter and/or enhancer elements including any of those described herein, and any of those known to one of skill in the art.
- the TRE comprises an inducible promoter.
- the TRE may be a tissue-specific TRE, i.e., it is active in specific tissue(s) and/or organ(s).
- a tissue-specific TRE comprises one or more tissue-specific promoter and/or enhancer elements, and optionally one or more constitutive promoter and/or enhancer elements.
- tissue-specific promoter and/or enhancer elements can be isolated from genes specifically expressed in the tissue by methods well known in the art.
- Suitable promoters include, e.g., cytomegalovirus promoter (CMV) (Stinski et al. (1985) Journal of Virology 55(2): 431-441); CMV early enhancer/chicken [3-actin (CBA) promoter/rabbit P-globin intron (CAG) (Miyazaki et al. (1989) Gene 79(2): 269-277); CB SB (Jacobson et al. (2006) Molecular Therapy 13(6): 1074-1084); human elongation factor la promoter (EFla) (Kim et al.
- CMV cytomegalovirus promoter
- CBA CMV early enhancer/chicken [3-actin (CBA) promoter/rabbit P-globin intron
- CB SB Jacobson et al. (2006) Molecular Therapy 13(6): 1074-1084
- EFla human elongation factor la promoter
- the TRE comprises a cytomegalovirus (CMV) promoter/enhancer, an SV40 promoter, a chicken beta actin (CBA) promoter, an smCBA promoter, a human elongation factor 1 alpha (EFla) promoter, a minute virus of mouse (MVM) intron which comprises transcription factor binding sites, a human phosphoglycerate kinase (PGK1) promoter, a human ubiquitin C (Ubc) promoter, a human beta actin promoter, a human neuron-specific enolase (ENO2) promoter, a human beta-glucuronidase (GUSB) promoter, a rabbit beta-globin element, a human calmodulin 1 (CALM1) promoter, a human ApoE/C-I hepatic control region (HCR1).
- CMV cytomegalovirus
- CBA chicken beta actin
- smCBA smCBA promoter
- EFla e
- a human al -antitrypsin (hAAT) promoter an extended HCR1, a HS-CRM8 element of an hAAT promoter, a human transthyretin (TTR) promoter, and/or a human Methyl-CpG Binding Protein 2 (MeCP2) promoter.
- hAAT human al -antitrypsin
- TTR human transthyretin
- MeCP2 Methyl-CpG Binding Protein 2
- a transfer genome may comprise a TRE comprising a CMV enhancer, a CBA promoter, and the splice acceptor from exon 3 of the rabbit beta-globin gene, collectively called a CAG promoter.
- a transfer genome may comprise a TRE comprising a hybrid of CMV enhancer and CBA promoter followed by a splice donor and splice acceptor, collectively called a C ASI promoter region.
- a transfer genome may comprise a TRE comprising a HCR1 and hAAT promoter (also referred to as an LP1 promoter).
- the TRE is liver-specific.
- Exemplary liver-specific TREs may comprise one or more elements from, without limitation, the ApoA-I promoter, the ApoA-II promoter, the ApoA-IV promoter, the ApoB promoter, the ApoC-I promoter, the ApoC-II promoter, the ApoC-III promoter, the ApoE promoter, the albumin promoter, the a-fetoprotein promoter, the phosphoenolpyruvate carboxykinase 1 (PCK1) promoter, the phosphoenol pyruvate carboxykinase 2 (PCK2) promoter, the transthyretin (TTR) promoter, the a-antitrypsin (AAT or SERPINA1) promoter, the TK (thymidine kinase) promoter, the hemopexin promoter, the alcohol dehydrogenase 6 promoter, the cholesterol 7alpha-hydroxylase promoter, the factor
- the TRE is muscle specific.
- Exemplary 7 muscle-specific TREs may comprise one or more elements from, without limitation, the human skeletal muscle a- actin (EISA) promoter, the muscle creatine kinase (MCK) promoter, the MHCK7 promoter, the dMCK promoter, the tMCK promoter, the CK.6 promoter, the CK8 promoter, the CK8e promoter, the human desmin (DES) promoter or variant thereof, the cardiac troponin T (cTnT) promoter, the myosin light-chain (MLC2v) promoter, the human a-myosin heavy chain gene (aMHC) promoter, the MLC promoter, the human troponin I (TNNI1) promoter, the AUSEx3 promoter, the SPcA5- 12 promoter, the SP-301 promoter, the MH promoter, and the Sk-CRM4/DES promoter.
- EISA human skeletal muscle a- actin
- MCK7
- the native promoter for the transgene may be used.
- the native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression.
- the native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli.
- other native expression control elements such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.
- compositions compnsing an AAV as disclosed herein together with a pharmaceutically acceptable excipient, adjuvant, diluent, vehicle or carrier, or a combination thereof.
- a '‘pharmaceutically acceptable carrier’ includes any material which, when combined with an active ingredient of a composition, allows the ingredient to retain biological activity and without causing disruptive physiological reactions, such as an unintended immune reaction.
- Pharmaceutically acceptable carriers include water, phosphate buffered saline, emulsions such as oil/water emulsion, and wetting agents. Compositions comprising such carriers are formulated by well-known conventional methods such as those set forth in Remington’s Pharmaceutical Sciences, current ed., Mack Publishing Co., Easton Pa.
- the instant disclosure provides methods for transducing a cell.
- the methods generally comprise contacting the cell with an rAAV disclosed herein under conditions whereby the cell is transduced.
- the rAAV disclosed herein can be used to transduce cells in vitro, in vivo and ex vivo.
- the instant disclosure provides methods for delivering a transgene into a cell.
- the methods generally comprise comprising contacting the cell with an rAAV disclosed herein under conditions whereby the cell is transduced and the transgene is expressed.
- the rAAV disclosed herein can comprise a transgene under the control of a TRE.
- the instant disclosure provides methods for expressing a transgene in a cell, the method generally comprising contacting the cell with such an rAAV under conditions whereby the cell is transduced and the transgene is expressed.
- the transgene can encode a polypeptide and/or an RNA molecule, as described herein.
- the instant disclosure provides methods for producing a polypeptide and/or an RNA molecule in a cell, the method generally comprising contacting the cell with such an rAAV under conditions whereby the cell is transduced and the polypeptide and/or an RNA molecule is produced.
- the cell is in a subject and the rAAV is administered to the subject.
- the rAAV disclosed herein can be administered to a subject by all routes suitable for an rAAV, including, without limitation, intravenously, intraperitoneally, subcutaneously, intramuscularly, intrathecally, or intradermally.
- the subject is a member of any mammalian or nonmammalian species. Suitable subjects include, without limitation, humans, non-human primates, canines, felines, ungulates (e.g., equine, bovine, swine (e.g., pig)), avians, rodents (e.g., rats, mice), and other subjects.
- the subject is canine.
- the subject is human.
- the invention provides an rAAV as disclosed herein for use in medicine. In another aspect, the invention provides an rAAV as disclosed herein for use as therapy. In another aspect, the invention provides an rAAV as disclosed herein for use as a medicament.
- the instant disclosure provides packaging systems for recombinant preparation of a recombinant adeno-associated virus (rAAV) disclosed herein.
- packaging systems generally comprise: a first nucleotide encoding one or more AAV Rep proteins; a second nucleotide encoding a capsid protein of any of the AAVs as disclosed herein; and a third nucleotide sequence comprising any of the rAAV genome sequences as disclosed herein, wherein the packaging system is operative in a cell for enclosing the transfer genome in the capsid to form the AAV.
- the packaging system comprises a first vector comprising the first nucleotide sequence encoding the one or more AAV Rep proteins and the second nucleotide sequence encoding the AAV capsid protein, and a second vector comprising the third nucleotide sequence comprising the rAAV genome.
- a “vector” refers to a nucleic acid molecule that is a vehicle for introducing nucleic acids into a cell (e.g., a plasmid, a virus, a cosmid, an artificial chromosome, etc.).
- the packaging system further comprises a fourth nucleotide sequence comprising one or more helper virus genes.
- the fourth nucleotide sequence comprises adenoviral E2, E4, and VA genes.
- the packaging system further comprises a third vector (e.g. , a helper virus vector), comprising the fourth nucleotide sequence.
- the third vector may be an independent third vector, integral with the first vector, or integral with the second vector.
- the packaging system comprises a first vector comprising the first nucleotide sequence encoding one or more AAV Rep proteins, the second nucleotide sequence encoding one or more recombinant AAV capsid protein as disclosed herein, and the third nucleotide sequence comprising any of the rAAV genome sequences as disclosed herein, wherein the packaging system is operative in a cell for enclosing the transfer genome in the capsid to form the AAV.
- the packaging system further comprises a fourth nucleotide sequence comprising one or more helper virus genes.
- the fourth nucleotide sequence comprises adenoviral E2, E4, and VA genes.
- the packaging system further comprises a second vector (e.g. , a helper virus vector), comprising the fourth nucleotide sequence.
- the second vector may be an independent second vector, integral with the first vector.
- AAV Rep protein can be employed in the packaging systems disclosed herein.
- the Rep nucleotide sequence encodes an AAV2 Rep protein.
- Suitable AAV2 Rep proteins may include, without limitation, Rep 78/68 or Rep 68/52.
- the helper virus is selected from the group consisting of adenovirus, herpes virus (including herpes simplex virus (HSV)), poxvirus (such as vaccinia virus), cytomegalovirus (CMV), and baculovirus.
- the adenovirus genome comprises one or more adenovirus RNA genes selected from the group consisting of El, E2, E4 and VA.
- the adenovirus genome comprises one or more adenovirus RNA genes selected from the group consisting of E2, E4, and VA.
- the HSV genome comprises one or more of HSV genes selected from the group consisting of UL5/8/52, ICPO, ICP4, ICP22, and UL30/UL42.
- the vectors e.g.. first, second, and/or third vectors
- the vectors are contained within one or more plasmids.
- the first, second, and/or third vectors are contained within one or more recombinant helper viruses.
- the first vector and the third vector are contained within a recombinant helper virus.
- the second vector and the third vector are contained within a recombinant helper virus.
- the disclosure provides a method for recombinant preparation of an AAV as described herein, wherein the method comprises transfecting or transducing a cell with a packaging system as described herein under conditions operative for enclosing the rAAV genome in the capsid to form the rAAV as described herein.
- Exemplary’ methods for recombinant preparation of an rAAV include transient transfection (e.g. , with one or more transfection plasmids containing a first, and a second, and optionally a third vector as described herein), viral infection (e.g.
- helper viruses such as a adenovirus, poxvirus (such as vaccinia virus), herpes virus (including HSV, cytomegalovirus, or baculovirus, containing a first, and a second, and optionally a third vector as described herein)), and stable producer cell line transfection or infection (e.g, with a stable producer cell, such as a mammalian or insect cell, containing a Rep nucleotide sequence encoding one or more AAV Rep proteins and/or a Cap nucleotide sequence encoding one or more capsid proteins as described herein, and with a transfer genome as described herein being delivered in the form of a plasmid or a recombinant helper virus).
- a stable producer cell such as a mammalian or insect cell, containing a Rep nucleotide sequence encoding one or more AAV Rep proteins and/or a Cap nucleotide sequence encoding one or more capsid proteins as described herein,
- the instant disclosure provides a packaging system for preparation of an rAAV, wherein the packaging system comprises: a first nucleotide sequence encoding one or more AAV Rep proteins; a second nucleotide sequence encoding a capsid protein of any one of the AAVs described herein; a third nucleotide sequence comprising an rAAV genome sequence of any one of the AAVs described herein; and optionally a fourth nucleotide sequence comprising one or more helper virus genes (e.g, adenoviral E2, E4, and VA genes).
- helper virus genes e.g, adenoviral E2, E4, and VA genes.
- Example 1 AAV Capsid Library Generation and Liver and/or Muscle Enrichment
- a shuffled capsid library was generated using capsid sequences of AAV1 through AAV14, AAVrh8, and AAVrhlO as inputs. Briefly, nucleic acid molecules encoding each AAV capsid were digested to create fragments of approximately 200-400 base pairs in length, gel extracted, mixed, and assembled via PCR. The assembled shuffled capsids were then digested and ligated into a vector for subsequent virus generation. Virus was produced using standard triple plasmid transfection techniques. Virus was then collected and harvested via precipitation with PEG 8000.
- Non-functional capsids were removed via ultracentrifugation in an iodixanol gradient, and buffer exchange of the 40% iodixanol fraction. See. e.g., Zolotukhin et al. (1999) Gene Therapy 6(6): 973-985. Nucleic acid encoding functional capsids were then extracted from the virus preparation using PCR, and the process of viral production was repeated with the functional viral capsid nucleic acids.
- an rAAV vector comprising a first coding sequence encoding canine FGF21 and second coding sequence encoding a soluble form of canine transforming growth factor-beta receptor 2 (sTGFbR2; see, e.g., Davidsohn et al. (2019) Proc. Natl. Acad. Sci. USA 116 (47): 23505-2351 1) was packaged into CL01, CL03, CL11, CL13, CL27, or AAV8 capsids. A total of 30 young adult (1- to 3-year old) naive male and female Beagle dogs were intravenously administered the CL01, CL03, CL11.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des protéines de capside de virus adéno-associé (AAV) recombinant, des compositions ( par exemple, rAAV) comprenant les protéines de capside, des acides nucléiques codant pour les protéines de capside, et des procédés de fabrication et d'utilisation des protéines de capside.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263376470P | 2022-09-21 | 2022-09-21 | |
US63/376,470 | 2022-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024064782A2 true WO2024064782A2 (fr) | 2024-03-28 |
Family
ID=90455263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/074729 WO2024064782A2 (fr) | 2022-09-21 | 2023-09-21 | Capsides de virus adéno-associé |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024064782A2 (fr) |
-
2023
- 2023-09-21 WO PCT/US2023/074729 patent/WO2024064782A2/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210316014A1 (en) | Nucleic acid constructs and methods of use | |
EP4004214A1 (fr) | Élément régulateur d'acide nucléique modifié et ses procédés d'utilisation | |
CN114269926A (zh) | Aav工程化 | |
US20230183659A1 (en) | Methods and compositions for the purification of adeno-associated virus | |
US20230045171A1 (en) | Adeno-associated virus compositions and methods of use thereof | |
US20240110201A1 (en) | Compositions and Methods for Treating Hereditary Angioedema | |
US20230055381A1 (en) | Adeno-associated virus packaging systems | |
WO2024064782A2 (fr) | Capsides de virus adéno-associé | |
WO2024097949A1 (fr) | Systèmes d'expression génique régulables à base d'aptazyme | |
US20230399657A1 (en) | Liver de-targeted recombinant aav capsid proteins | |
US20230323395A1 (en) | Methods and compositions for the production of adeno-associated virus | |
KR20230029616A (ko) | 종간 호환가능한 아데노-관련 바이러스 조성물 및 이의 사용 방법 | |
US20230090654A1 (en) | Adeno-associated virus formulations | |
US20230112648A1 (en) | Non-naturally occurring polyadenylation elements and methods of use thereof | |
WO2023242633A2 (fr) | Protéines de capside de vaa recombinant | |
KR20230003554A (ko) | 낮은 전사 활성을 갖는 프로모터를 사용하여 뉴클레아제 발현 및 표적-외 활성을 감소시키기 위한 조성물 및 방법 | |
WO2023194796A2 (fr) | Protéines de capside de vaa recombinant | |
CN117120076A (zh) | 用于治疗遗传性血管性水肿的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23869164 Country of ref document: EP Kind code of ref document: A2 |